Elizabeth A. Brown
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Elizabeth A. Brown has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Pardis C. Sabeti
Broad Institute of Massachusetts Institute of Technology and Harvard, Boston, Massachusetts, USA
3 shared publications - Stephen F. Schaffner
Broad Institute
3 shared publications - Aaron E. Lin
Department of Molecular Biology, Princeton University , Princeton, NJ 08544
2 shared publications - Courtney L. Finch
Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA
2 shared publications - Erica Ollmann Saphire
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, USA
2 shared publications - Jens H. Kuhn
Department of Microbiology, Global Health Emergent Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
2 shared publications
Latest Publications
- 31 October 2023
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 33 (3) , 270-283
Three linked variants have opposing regulatory effects on isovaleryl-CoA dehydrogenase gene expression
While genome-wide association studies (GWAS) and positive selection scans identify genomic loci driving human phenotypic diversity, functional validation is required to discover the variant(s) responsible. We dissected the IVD gene locus—which encodes the isovaleryl-CoA dehydrogenase enzyme—implicated by selection statistics, multiple GWAS, and clinical genetics as important to function and fitness. We combined luciferase assays, CRISPR/Cas9 genome-editing, massively parallel reporter assays (MPRA), and a deletion tiling MPRA strategy across regulatory loci. We identified three regulatory variants, including an indel, that may underpin GWAS signals for pulmonary fibrosis and testosterone, and that are linked on a positively selected haplotype in the Japanese population. These regulatory variants exhibit synergistic and opposing effects on IVD expression experimentally. Alleles at these variants lie on a haplotype tagged by the variant most strongly associated with IVD expression and metabolites, but with no functional evidence itself. This work demonstrates how comprehensive functional investigation and multiple technologies are needed to discover the true genetic drivers of phenotypic diversity.
- 31 October 2023
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 33 (3) , 270-283
Three linked variants have opposing regulatory effects on isovaleryl-CoA dehydrogenase gene expression
While genome-wide association studies (GWAS) and positive selection scans identify genomic loci driving human phenotypic diversity, functional validation is required to discover the variant(s) responsible. We dissected the IVD gene locus—which encodes the isovaleryl-CoA dehydrogenase enzyme—implicated by selection statistics, multiple GWAS, and clinical genetics as important to function and fitness. We combined luciferase assays, CRISPR/Cas9 genome-editing, massively parallel reporter assays (MPRA), and a deletion tiling MPRA strategy across regulatory loci. We identified three regulatory variants, including an indel, that may underpin GWAS signals for pulmonary fibrosis and testosterone, and that are linked on a positively selected haplotype in the Japanese population. These regulatory variants exhibit synergistic and opposing effects on IVD expression experimentally. Alleles at these variants lie on a haplotype tagged by the variant most strongly associated with IVD expression and metabolites, but with no functional evidence itself. This work demonstrates how comprehensive functional investigation and multiple technologies are needed to discover the true genetic drivers of phenotypic diversity.
- Open Access
- 7 August 2023
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 10 (10) , 1725-1737
SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis
Objective: To investigate the serologic response, predictors of response, and clinical outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis (RMS) from DAYBREAK. Methods: DAY-BREAK (ClinicalTrials.gov-NCT02576717), an open-label extension study of oral ozanimod 0.92 mg, enrolled participants aged 18-55 years with RMS who completed phase 1-3 ozanimod trials. Participants who were fully vaccinated against SARS-CoV-2 with mRNA or non-mRNA vaccines, were unvaccinated, and/or had COVID-19-related adverse events (AEs, with or without vaccina-tion) and postvaccination serum samples were included (n = 288). Spike recep-tor binding domain (RBD) antibody levels (seroconversion: =0.8 U/mL) and serologic evidence of SARS-CoV-2 infection (nucleocapsid IgG: =1 U/mL) were assessed (Roche Elecsys/Cobas e411 platform). Results: In fully vaccinated par-ticipants (n = 148), spike RBD antibody seroconversion occurred in 90% (n = 98/109) of those without serologic evidence of prior SARS-CoV-2 expo -sure (100% [n = 80/80] seroconversion after mRNA vaccination) and in 100% (n = 39/39) of participants with serologic evidence of viral exposure. mRNA vaccination predicted higher spike RBD antibody levels, whereas absolute lym-phocyte count (ALC), age, body mass index, and sex did not. COVID-19- related AEs were reported in 10% (n = 15/148) of fully vaccinated participants -all were nonserious and not severe; all participants recovered. Interpretation: Most ozanimod-treated participants with RMS mounted a serologic response to SARS-CoV-2 vaccination and infection, regardless of participant characteristics or ALC levels. In this analysis, all COVID-19-related AEs post-full vaccination in participants taking ozanimod were nonserious and not severe.
- 7 August 2023
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 10 (10) , 1725-1737
Open AccessSARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis
Objective: To investigate the serologic response, predictors of response, and clinical outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis (RMS) from DAYBREAK. Methods: DAY-BREAK (ClinicalTrials.gov-NCT02576717), an open-label extension study of oral ozanimod 0.92 mg, enrolled participants aged 18-55 years with RMS who completed phase 1-3 ozanimod trials. Participants who were fully vaccinated against SARS-CoV-2 with mRNA or non-mRNA vaccines, were unvaccinated, and/or had COVID-19-related adverse events (AEs, with or without vaccina-tion) and postvaccination serum samples were included (n = 288). Spike recep-tor binding domain (RBD) antibody levels (seroconversion: =0.8 U/mL) and serologic evidence of SARS-CoV-2 infection (nucleocapsid IgG: =1 U/mL) were assessed (Roche Elecsys/Cobas e411 platform). Results: In fully vaccinated par-ticipants (n = 148), spike RBD antibody seroconversion occurred in 90% (n = 98/109) of those without serologic evidence of prior SARS-CoV-2 expo -sure (100% [n = 80/80] seroconversion after mRNA vaccination) and in 100% (n = 39/39) of participants with serologic evidence of viral exposure. mRNA vaccination predicted higher spike RBD antibody levels, whereas absolute lym-phocyte count (ALC), age, body mass index, and sex did not. COVID-19- related AEs were reported in 10% (n = 15/148) of fully vaccinated participants -all were nonserious and not severe; all participants recovered. Interpretation: Most ozanimod-treated participants with RMS mounted a serologic response to SARS-CoV-2 vaccination and infection, regardless of participant characteristics or ALC levels. In this analysis, all COVID-19-related AEs post-full vaccination in participants taking ozanimod were nonserious and not severe.
- Open Access
- 7 January 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (4) , 100661
Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial
- 7 January 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (4) , 100661
Open AccessEffect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial
- Open Access
Reporter Assays for Ebola Virus Nucleoprotein Oligomerization, Virion-Like Particle Budding, and Minigenome Activity Reveal the Importance of Nucleoprotein Amino Acid Position 111
For highly pathogenic viruses, reporter assays that can be rapidly performed are critically needed to identify potentially functional mutations for further study under maximal containment (e.g., biosafety level 4 [BSL-4]). The Ebola virus nucleoprotein (NP) plays multiple essential roles during the viral life cycle, yet few tools exist to study the protein under BSL-2 or equivalent containment. Therefore, we adapted reporter assays to measure NP oligomerization and virion-like particle (VLP) production in live cells and further measured transcription and replication using established minigenome assays. As a proof-of-concept, we examined the NP-R111C substitution, which emerged during the 2013–2016 Western African Ebola virus disease epidemic and rose to high frequency. NP-R111C slightly increased NP oligomerization and VLP budding but slightly decreased transcription and replication. By contrast, a synthetic charge-reversal mutant, NP-R111E, greatly increased oligomerization but abrogated transcription and replication. These results are intriguing in light of recent structures of NP oligomers, which reveal that the neighboring residue, K110, forms a salt bridge with E349 on adjacent NP molecules. By developing and utilizing multiple reporter assays, we find that the NP-111 position mediates a complex interplay between NP’s roles in protein structure, virion budding, and transcription and replication.
Open AccessReporter Assays for Ebola Virus Nucleoprotein Oligomerization, Virion-Like Particle Budding, and Minigenome Activity Reveal the Importance of Nucleoprotein Amino Acid Position 111
For highly pathogenic viruses, reporter assays that can be rapidly performed are critically needed to identify potentially functional mutations for further study under maximal containment (e.g., biosafety level 4 [BSL-4]). The Ebola virus nucleoprotein (NP) plays multiple essential roles during the viral life cycle, yet few tools exist to study the protein under BSL-2 or equivalent containment. Therefore, we adapted reporter assays to measure NP oligomerization and virion-like particle (VLP) production in live cells and further measured transcription and replication using established minigenome assays. As a proof-of-concept, we examined the NP-R111C substitution, which emerged during the 2013–2016 Western African Ebola virus disease epidemic and rose to high frequency. NP-R111C slightly increased NP oligomerization and VLP budding but slightly decreased transcription and replication. By contrast, a synthetic charge-reversal mutant, NP-R111E, greatly increased oligomerization but abrogated transcription and replication. These results are intriguing in light of recent structures of NP oligomers, which reveal that the neighboring residue, K110, forms a salt bridge with E349 on adjacent NP molecules. By developing and utilizing multiple reporter assays, we find that the NP-111 position mediates a complex interplay between NP’s roles in protein structure, virion budding, and transcription and replication.
- Open Access
Reporter assays for Ebola virus nucleoprotein oligomerization, virion-like particle budding, and minigenome activity reveal the importance of nucleoprotein amino acid position 111
For highly pathogenic viruses, reporter assays that can be rapidly performed are critically needed to identify potentially functional mutations for further study under maximal containment (e.g., biosafety level 4 [BSL-4]). The Ebola virus nucleoprotein (NP) plays multiple essential roles during the viral life cycle, yet few tools exist to study the protein under BSL-2 or equivalent containment. Therefore, we adapted reporter assays to measure NP oligomerization and virion-like particle (VLP) production in live cells and further measure transcription and replication using established minigenome assays. As a proof-of-concept, we examined the NP-R111C substitution, which emerged during the 2013–2016 Western African Ebola virus disease epidemic and rose to high frequency. NP-R111C slightly increased NP oligomerization and VLP budding but slightly decreased transcription and replication. By contrast, a synthetic charge-reversal mutant, NP-R111E, greatly increased oligomerization but abrogated transcription and replication. These results are intriguing in light of recent structures of NP oligomers, which reveal that the neighboring residue, K110, forms a salt bridge with E349 on adjacent NP molecules. By developing and utilizing multiple reporter assays, we find that the NP-111 position mediates a complex interplay between NP’s roles in protein structure, virion budding, and transcription and replication.
Open AccessReporter assays for Ebola virus nucleoprotein oligomerization, virion-like particle budding, and minigenome activity reveal the importance of nucleoprotein amino acid position 111
For highly pathogenic viruses, reporter assays that can be rapidly performed are critically needed to identify potentially functional mutations for further study under maximal containment (e.g., biosafety level 4 [BSL-4]). The Ebola virus nucleoprotein (NP) plays multiple essential roles during the viral life cycle, yet few tools exist to study the protein under BSL-2 or equivalent containment. Therefore, we adapted reporter assays to measure NP oligomerization and virion-like particle (VLP) production in live cells and further measure transcription and replication using established minigenome assays. As a proof-of-concept, we examined the NP-R111C substitution, which emerged during the 2013–2016 Western African Ebola virus disease epidemic and rose to high frequency. NP-R111C slightly increased NP oligomerization and VLP budding but slightly decreased transcription and replication. By contrast, a synthetic charge-reversal mutant, NP-R111E, greatly increased oligomerization but abrogated transcription and replication. These results are intriguing in light of recent structures of NP oligomers, which reveal that the neighboring residue, K110, forms a salt bridge with E349 on adjacent NP molecules. By developing and utilizing multiple reporter assays, we find that the NP-111 position mediates a complex interplay between NP’s roles in protein structure, virion budding, and transcription and replication.
- 1 January 2008
- Published by Field Museum of Natural History in Fieldiana Botany
- Vol. 47 (1) , 159
Chapter Fourteen: Mnioloma (Calypogeiaceae: Jungermanniopsida) in Australasia: how many species are there
- 1 January 2008
- Published by Field Museum of Natural History in Fieldiana Botany
- Vol. 47 (1) , 159
Chapter Fourteen: Mnioloma (Calypogeiaceae: Jungermanniopsida) in Australasia: how many species are there
- 10 November 2003
- Published by CSIRO Publishing in Australian Systematic Botany
- Vol. 16 (5) , 595-619
A revision of Lissanthe (Styphelioideae: Ericaceae)
A revision of the styphelioid genus Lissanthe recognises seven species and two subspecies: L. brevistyla A.R.Bean, L. sapida R.Br., L. strigosa (Sm.) R.Br. subsp. strigosa , L. strigosa subsp. subulata (R.Br.) J.M.Powell. New combinations are made for two species transferred from Leucopogon : Lissanthe rubicunda (F.Muell.) J.M.Powell, D.M.Crayn & E.A.Br. and Lissanthe pluriloculata (F.Muell.) J.M.Powell, D.M.Crayn & E.A.Br. Two new species from Western Australia, Lissanthe powelliae D.M.Crayn & E.A.Br. and L. scabra D.M.Crayn & E.A.Br. are described, and Lissanthe sapida is lectotypified. Keys, illustrations and distribution maps are provided for all taxa. Lissanthe as defined here is a strongly supported clade based on analyses of sequence data from two chloroplast loci, the atpB–rbcL intergenic spacer and the matK gene. Potential morphological synapomorphies for Lissanthe include flowers pedicellate above the bracteoles, styles hairy at least at the base, and leaves with an abaxial surface that is grooved longitudinally.
- 10 November 2003
- Published by CSIRO Publishing in Australian Systematic Botany
- Vol. 16 (5) , 595-619
A revision of Lissanthe (Styphelioideae: Ericaceae)
A revision of the styphelioid genus Lissanthe recognises seven species and two subspecies: L. brevistyla A.R.Bean, L. sapida R.Br., L. strigosa (Sm.) R.Br. subsp. strigosa , L. strigosa subsp. subulata (R.Br.) J.M.Powell. New combinations are made for two species transferred from Leucopogon : Lissanthe rubicunda (F.Muell.) J.M.Powell, D.M.Crayn & E.A.Br. and Lissanthe pluriloculata (F.Muell.) J.M.Powell, D.M.Crayn & E.A.Br. Two new species from Western Australia, Lissanthe powelliae D.M.Crayn & E.A.Br. and L. scabra D.M.Crayn & E.A.Br. are described, and Lissanthe sapida is lectotypified. Keys, illustrations and distribution maps are provided for all taxa. Lissanthe as defined here is a strongly supported clade based on analyses of sequence data from two chloroplast loci, the atpB–rbcL intergenic spacer and the matK gene. Potential morphological synapomorphies for Lissanthe include flowers pedicellate above the bracteoles, styles hairy at least at the base, and leaves with an abaxial surface that is grooved longitudinally.
- Open Access
- 1 July 2002
- Published by S. Karger AG in Digestive Diseases
- Vol. 20 (3-4) , 297-298
Contents Vol. 20, 2002
- 1 July 2002
- Published by S. Karger AG in Digestive Diseases
- Vol. 20 (3-4) , 297-298
Open AccessContents Vol. 20, 2002
- Open Access
- 5 January 2002
- Published by Royal Botanical Gardens and Domain Trust in Telopea
- Vol. 9 (3) , 435-438
A new species of Radula Sect. Cavifolium (Radulaceae: Hepaticae) from Queensland, Australia
- 5 January 2002
- Published by Royal Botanical Gardens and Domain Trust in Telopea
- Vol. 9 (3) , 435-438
Open AccessA new species of Radula Sect. Cavifolium (Radulaceae: Hepaticae) from Queensland, Australia